Тетрациклины в лечении бактериальных инфекций - акцент на омадациклин

Автор: Кошкарова А.М., Ортенберг Э.А.

Журнал: Тюменский медицинский журнал @tmjournal

Статья в выпуске: 2 (87) т.25, 2023 года.

Бесплатный доступ

Применение омадациклина в рамках лечения бактериальных инфекций позволяет позитивно оценить его клиническую эффективность. Имеются основания для включения омадациклина в актуальные клинические рекомендации, наряду с уже представленными там тетрациклинами.

Омадациклин, новые тетрациклины, бактериальные инфекции

Короткий адрес: https://sciup.org/140303405

IDR: 140303405

Список литературы Тетрациклины в лечении бактериальных инфекций - акцент на омадациклин

LaPlante K. et al. Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. //Ann Med.2022. № 54(1): р. 1686-1700.
Villano S. et al. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. //Future microbiology. 2016. № 11, р. 1421-1434.
Zhanel G. et al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. //Drugs. 2020. № 80. Р. 285-313.
Асямов К.В. и др. Новые возможности антибактериальной терапии. //Лечение и профилактика. 2020.Том 10. № 4. С. 108.
Draper M.P. et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. //Antimicrobial agents and chemotherapy. 2014. V. 58. 1279-1283.
Rodvold K.A. et al. Omadacycline. A Review of the Clinical Pharmacokinetics and Pharmacodynamics. //Clinical Pharmacokinetics. 2019. Nov 27.
Leviton I.M., Amodio-Groton M. Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection. //Clin Drug Investig. 2022 V. 42 (3): р. 193-197
Torres A. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. //International journal of infectious diseases. Jun. 20, 2021.
Stets R. et al. Omadacycline for Community-Acquired Bacterial Pneumonia. //N Engl J. Med. 2019. V. 380: р.517-527
Overcash J. et al. Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study. //Antimicrob Agents Chemother. 2019. V. 63(5): e 02083-18.
Durães F., Sousa E. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. //Pharmaceuticals (Basel). 2019. V. 21. № 12 (2): р 63.
Rizzo А., Moniri N. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use. //BMC Infect Dis. 2022; № 22: р. 874.
Pearson J. Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series. //Open Forum Infect Dis. 2020. № 7(10): р. 415.
BichHanh B.T. et al. Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus.Frontiers in Pharmacology. 2021. № 20; р. 20.
Abrahamain F., Sakoulas G. Omadacycline for Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019. № 15; V. 69: р. 23-32.
Waites K. et al. Omadacycline Is Highly Active In Vitro against Mycoplasma genitalium. //MicrobiolSpectr. 2022. № 10(6): р. 22.
Liu P.Y. et al. In vitro activity of cefiderocol, cefepime/ enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacterbaumannii isolates associated from bloodstream infection in Taiwan between 2018-2020. //J. Microbiol Immunol Infect. 2022. V. 55(5): р. 888-895.
Y. Yang et al. In vitro activity of cefepime-zidebactam, ceftazidime-avibactam, and other comparators against clinical isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacterbaumannii: results from China Antimicrobial Surveillance Network (CHINET) in 2018. //Antimicrob Agents Chemother. 2020.V. 65.
Abbey T. et al. Activity of Omadacycline Alone and in Combination against Carbapenem-NonsusceptibleAcinetobacterbauman nii with Varying Minocycline Susceptibility. //Microbiology Spectrum. 2022. V. 20. № 10 (3). Р. 13.
Dubois J., Dubois M., Martel J. In Vitro and Intracellular Activities of Omadacycline against Legionella pneumophila. //Antimicrob Agents Chemother. 2020. V. 64(5): e 01972-19.
Baker D. Omadacycline. //Hosp Pharm. 2019. V. 54(2): р. 80-87.
Garey K. et al. Omadacycline and Clostridioides difficile. //A Systematic Review of Preclinical and Clinical Evidence. 2023. V. 57(2): 184-192.
Huijuan Li. et al. Efficacy and safety of optional parenteral antimicrobial therapy for complicated skin and soft tissue infections: A systematic review and Bayesian network metaanalysis Medicine (Baltimore). 2022. V. 26; 101(34): e30120.
Warner A. et al. Tetracyclines and bone: unclear actions with potentially lasting effects. //Bone. 2022. 159: р.116377.
Principi N. et al. Esposito New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue //Infections in Pediatrics Pharmaceuticals (Basel). 2020; № 13(11): р. 333.
Rusu A. et al. The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. //Pharmaceutics. 2021. № 13(12): р. 2085.
O’Riordan W. et al. Omadacycline for acute bacterial skin and skin-structure infections. //N Engl J Med. 2019. V. 380: р.528-38.
Ramirez J.A. et al. Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to ClinicalPractice// Clin Infect Dis. 2019. № 15. 69(Suppl 1): S33–S39.

Еще

Статья обзорная